Litcius/Paper detail

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

Aitana Juan-Giner, Maria L Namulwana, Derick Kimathi, Kyra H. Grantz, Gamou Fall, Moussa Dia, Ndeye Sakha Bob, Amadou Alpha Sall, Caroline Nerima, Mateus Kambale Sahani, Edgar Mulogo, Immaculate Ampeire, Joachim Hombach, Deborah Nanjebe, Juliet Mwanga‐Amumpaire, Derek A. T. Cummings, Philip Bejon, George M. Warimwe, Rebecca F. Grais

2023The Lancet Infectious Diseases13 citationsDOI

Topics & Concepts

MedicineVaccinationSeroconversionPopulationImmunogenicityRandomized controlled trialPediatricsInternal medicineImmunologyAntibodyEnvironmental healthMosquito-borne diseases and controlViral Infections and Outbreaks ResearchVibrio bacteria research studies
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial | Litcius